Copyright ©The Author(s) 2015.
World J Stem Cells. Jun 26, 2015; 7(5): 793-805
Published online Jun 26, 2015. doi: 10.4252/wjsc.v7.i5.793
Table 1 Clinical studies with endogenous cardiac stem cells
StudyDesignPopulationInterventionNo. of patientsreceiving treatmentPrimary endpointConclusion
CADUCEUSRCTPost-MI with LVEF 25%-45%Intracoronary infusion of CDCs17Occurrence of death, new MI, new cardiac tumour on MRI and/or admission for HFSafety proven; MRI-scar reduction and increase in viable myocardium
SCIPIORCTPost-MI with LVEF ≤ 40%Intracoronary infusion of autologous16Short-term safetySafety proven; LVEF improvement, infarct size reduction
c-kit+ CSCs
ALCADIANon-randomizedIschemic CMP with LVEF 15%-35%Intramyocardial injection of autologous CSCs with bFGF6-No adverse events; improvement of NYHA class and LVEF